Company intelligence / Profile preview

CeNeS Pharmaceuticals

Cambridge/Histon, Cambridgeshire, United Kingdompaion.com ↗

Ownership: Private
Employees: ~15
Development stage: Other

Overview

CeNeS developed a portfolio of small molecule drugs for CNS disorders with lead assets including M6G (morphine derivative for post-operative pain, reached Phase III), CNS 5161 (for neuropathic/cancer pain, Phase IIa), and short acting sedative CNS 7056X. The company was acquired by Paion in 2008; some assets like Remimazolam have since advanced under new ownership.

Therapeutic areas: NeurologyCardiovascularOther
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

morphine 6-glucuronide

2 more assets in the full pipeline.

Request access →

Partnerships

Lundbeck

Beyond the preview

Go deeper on CeNeS Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CeNeS Pharmaceuticals.

Explore the full profile